ArticleTranslational lung cancer research2026
Assessment of tumor mutation burden based on whole-exome sequencing of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid in advanced non-small cell lung cancer treated with pembrolizumab: a prospective, multicenter, observational study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obtaining sufficient tumor tissue for molecular testing remains challenging in advanced non-small cell lung cancer (NSCLC). We evaluated tumor mutation burden (TMB) using extracellular vesicle (EV)-derived DNA from bronchoalveolar lavage fluid (BALF) and assessed the correlation between BALF and tissue TMB. Methods: In this prospective, multicenter, observational study, we enrolled patients with pathologically confirmed stage IV NSCLC who received pembrolizumab at three academic institutions in South Korea. TMB was quantified by whole-exome sequencing (WES) of EV-derived DNA isolated from BALF and from matched tumor tissue obtained prior to treatment. The concordance of TMB between BALF EV-derived DNA and matched tumor tissue was assessed using Spearman's rank correlation coefficient. Associations between BALF EV-TMB and clinical outcomes-including overall survival (OS), progression-free survival (PFS), and objective response rate-were evaluated over a median follow-up of 17.0 months (range, 1-63 months). Results: Out of 64 patients, 46 (71.9%) had evaluable tissue TMB, and 53 (82.8%) had evaluable BALF TMB. There were no significant differences between BALF and tissue regarding DNA amounts, estimated library size, mean depth, and uniformity. The median tissue TMB and BALF TMB were 4.738 and 1.82 mut/Mb, respectively. A modest positive correlation was observed between tissue TMB and BALF TMB (r=0.61, P<0.001). Neither tissue TMB nor BALF TMB showed significant differences in PFS. However, higher TMB is associated with a more favorable OS outcome in patients with advanced NSCLC. Conclusions: These findings demonstrate the feasibility of WES-based TMB quantification from BALF EV-derived DNA and suggest its potential as a complementary prognostic measure in pembrolizumab-treated NSCLC. Validation in larger, prospective cohorts is warranted before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.